Synthesis, in vitro profiling, and in vivo efficacy studies of a new family of multitarget antiAlzheimer compounds
Simultaneous modulation of several targets or athological events with a key pathogenic role is a promising strategy to tackle thus far difficult-to-cure or incurable multifactorial diseases, such as Alzheimer's disease (AD). In this scenario, multitarget compounds, i.e., single molecules that h...
| Autores: | , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:217035 |
| Acceso en línea: | https://ddd.uab.cat/record/217035 https://dx.doi.org/urn:doi:10.3390/proceedings2019022071 |
| Access Level: | acceso abierto |
| Palabra clave: | Multitarget compounds Multitarget-directed ligands Acetylcholinesterase inhibitors Butyrylcholinesterase inhibitors BACE-1 inhibitors Anti-aggregating agents Antioxidant Properties brain permeability in vivo efficacy studies |
| Sumario: | Simultaneous modulation of several targets or athological events with a key pathogenic role is a promising strategy to tackle thus far difficult-to-cure or incurable multifactorial diseases, such as Alzheimer's disease (AD). In this scenario, multitarget compounds, i.e., single molecules that hit several targets, are superior to other multitarget strategies that are based on the use of more than one drug (drug cocktails, fixed-dose combinations), in terms of simpler drug development and better patient compliance, efficiency, and safety. |
|---|